Mitsutake N - Search Results

1

Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest.

Bulgin D, Podtcheko A, Takakura S, Mitsutake N, Namba H, Saenko V, Ohtsuru A, Rogounovitch T, Palona I, Yamashita S. Bulgin D, et al. Among authors: mitsutake n. Thyroid. 2006 Mar;16(3):217-24. doi: 10.1089/thy.2006.16.217. Thyroid. 2006. PMID: 16571083

2

PKC delta mediates ionizing radiation-induced activation of c-Jun NH(2)-terminal kinase through MKK7 in human thyroid cells.

Mitsutake N, Namba H, Shklyaev SS, Tsukazaki T, Ohtsuru A, Ohba M, Kuroki T, Ayabe H, Yamashita S. Mitsutake N, et al. Oncogene. 2001 Feb 22;20(8):989-96. doi: 10.1038/sj.onc.1204179. Oncogene. 2001. PMID: 11314034

3

Transient activation of c-Jun NH2-terminal kinase by growth factors influences survival but not apoptosis of human thyrocytes.

Shklyaev SS, Namba H, Mitsutake N, Alipov G, Nagayama Y, Maeda S, Ohtsuru A, Tsubouchi H, Yamashita S. Shklyaev SS, et al. Among authors: mitsutake n. Thyroid. 2001 Jul;11(7):629-36. doi: 10.1089/105072501750362691. Thyroid. 2001. PMID: 11484891

4

Involvement of wild-type p53 in radiation-induced c-Jun N-terminal kinase activation in human thyroid cells.

Shklyaev SS, Namba H, Sautin Y, Mitsutake N, Nagayama Y, Ishikawa N, Ito K, Zeki K, Yamashita S. Shklyaev SS, et al. Among authors: mitsutake n. Anticancer Res. 2001 Jul-Aug;21(4A):2569-75. Anticancer Res. 2001. PMID: 11724323

5

Tie-2 and angiopoietin-1 expression in human thyroid tumors.

Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, Yamashita S. Mitsutake N, et al. Thyroid. 2002 Feb;12(2):95-9. doi: 10.1089/105072502753522310. Thyroid. 2002. PMID: 11916292

6

Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer.

Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S. Ishigaki K, et al. Among authors: mitsutake n. J Clin Endocrinol Metab. 2002 Jul;87(7):3433-40. doi: 10.1210/jcem.87.7.8648. J Clin Endocrinol Metab. 2002. PMID: 12107263

7

The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.

Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S. Podtcheko A, et al. Among authors: mitsutake n. J Clin Endocrinol Metab. 2003 Apr;88(4):1889-96. doi: 10.1210/jc.2002-021230. J Clin Endocrinol Metab. 2003. PMID: 12679488

8

Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation.

Kumagai A, Namba H, Mitsutake N, Saenko VA, Ohtsuru A, Ito M, Noh JY, Sugino K, Ito K, Yamashita S. Kumagai A, et al. Among authors: mitsutake n. Oncol Rep. 2006 Jul;16(1):123-6. Oncol Rep. 2006. PMID: 16786134

9

BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.

Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S. Palona I, et al. Among authors: mitsutake n. Endocrinology. 2006 Dec;147(12):5699-707. doi: 10.1210/en.2006-0400. Epub 2006 Sep 7. Endocrinology. 2006. PMID: 16959844

10

Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status.

Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S. Abrosimov A, et al. Among authors: mitsutake n. Int J Cancer. 2007 Jan 1;120(1):196-200. doi: 10.1002/ijc.22290. Int J Cancer. 2007. PMID: 17044028

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters